FindTrial
Sign In

ToGA study: A Study of R597 (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer.

ToGA study: A Study of R597 (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer.

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220186
Enrollment
Unknown
Registered
2005-12-12
Start date
2005-12-12
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Cancer

Interventions

investigational material(s) Generic name etc : R597 (Trastuzumab) INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigation

Sponsors

Chugai Pharmaceutical Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inclusion criteria: -Male or Female patients (>=18 years of age); -Inoperable locally advanced, recurrent, or metastatic cancer of the stomach or gastroesophageal junction; -Adenocarcinoma; -HER2-positive tumors. Exclusion criteria: -Previous chemotherapy for adavanced/metastatic disease; -Lack of physical integrity of the upper gastrointestinal tract, malabsorption syndrome; -History of cardiac deisease; -Dyspnoea at rest, due to complications of advanced malignancy or other disease, or patients who require supportive oxygen therapy.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Primary endpoint: Overall survival (OS)—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026